Mar 2, 2026 06:55AM
Mar 2, 2026 06:50AM
Jan 12, 2026 06:50AM
Jan 12, 2026 06:50AM
Dec 3, 2025 06:50AM
Dec 3, 2025 06:50AM
Nov 12, 2025 06:50AM Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
Nov 10, 2025 06:50AM
Aug 12, 2025 04:05PM
Jul 10, 2025 06:51AM
Jul 10, 2025 06:50AM
Jun 16, 2025 06:50AM
Jun 16, 2025 06:50AM
Jun 2, 2025 06:52AM Pharvaris (PHVS) Presents Data Supporting Ongoing Clinical Development of Deucrictibant
Jun 2, 2025 06:50AM
May 13, 2025 04:05PM
Apr 7, 2025 06:58AM
Apr 1, 2025 06:50AM
Apr 1, 2025 06:50AM
Mar 3, 2025 06:50AM
Mar 3, 2025 06:50AM Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
Jan 13, 2025 06:52AM
Jan 13, 2025 06:50AM
Nov 13, 2024 04:10PM
Oct 24, 2024 08:00AM
Sep 5, 2024 06:50AM
Sep 5, 2024 06:50AM
Sep 5, 2024 06:50AM Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
Sep 5, 2024 06:49AM
Sep 5, 2024 06:48AM
Aug 14, 2024 06:50AM
Aug 1, 2024 08:00AM
Jun 4, 2024 06:50AM
May 14, 2024 02:20AM
May 8, 2024 04:10PM Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
Apr 10, 2024 04:10PM
Apr 10, 2024 04:09PM
Apr 10, 2024 04:08PM
Mar 18, 2024 06:50AM
Feb 22, 2024 06:50AM
Feb 22, 2024 06:50AM
Jan 22, 2024 06:50AM Pharvaris (PHVS) Announces FDA Lifting of the Clinical Hold of Deucrictibant
Jan 22, 2024 06:50AM
Jan 5, 2024 06:50AM
Jan 5, 2024 06:50AM
Dec 11, 2023 04:12AM
Dec 8, 2023 06:00PM
Dec 6, 2023 03:55PM
Dec 6, 2023 06:52AM Pharvaris (PHVS) Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
Dec 6, 2023 06:50AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All